Pancreatic Cancer Research

ResearcherHeartlands HospitalActive in the last 2 years

Sarah F. Powell-Brett

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4488-6862; OpenAlex author ID A5055654305. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2021: 3 papers · 2022: none · 2023: 6 papers · 2024: 3 papers · 2025: none · 2026: 4 papers

Papers 16

  1. Intention to treat outcomes following management of locally advanced pancreatic ductal adenocarcinoma with curative intent: single centre cohort study. Co-author DOI 10.1016/j.hpb.2026.06.008↗
  2. IGF2BP3-mediated regulation of the RNA isoform and modification landscape in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03933-3↗
  3. Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement. First author DOI 10.1111/ans.70977↗
  4. Intranetwork variation in neoadjuvant therapy delivery for borderline resectable and locally advanced pancreatic cancer: a UK multicentre cohort study. Co-author DOI 10.1308/rcsann.2026.0023↗
  5. Interplay in galectin expression predicts patient outcomes in a spatially restricted manner in PDAC. Co-author DOI 10.1016/j.biopha.2024.116283↗
  6. Effect of peri-adventitial superior mesenteric artery dissection on margin status during pancreaticoduodenectomy for resectable pancreatic cancer: the DISSECT … Co-author DOI 10.1093/bjsopen/zrae075↗
  7. Involvement of the Gut Microbiome in the Local and Systemic Immune Response to Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16050996↗
  8. Are physical performance and frailty assessments useful in targeting and improving access to adjuvant therapy in patients undergoing resection for pancreatic c… Co-author DOI 10.1007/s00423-023-02828-1↗
  9. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade. Co-author DOI 10.1158/2326-6066.cir-22-0121↗
  10. Recent Advances in Pancreatic Ductal Adenocarcinoma: Strategies to Optimise the Perioperative Nutritional Status in Pancreatoduodenectomy Patients. First author DOI 10.3390/cancers15092466↗
  11. Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies? Co-author DOI 10.3390/cancers15215140↗
  12. Resection of isolated liver oligometastatic disease in pancreatic ductal adenocarcinoma: Is there a survival benefit? A systematic review. First author DOI 10.4240/wjgs.v15.i7.1512↗
  13. Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma. Co-author DOI 10.7554/elife.86125↗
  14. Understanding pancreatic exocrine insufficiency and replacement therapy in pancreatic cancer. Co-author DOI 10.1016/j.ejso.2020.03.006↗
  15. Pancreatic enzyme replacement therapy in patients with pancreatic cancer: A national prospective study. Co-author DOI 10.1016/j.pan.2021.05.299↗
  16. Achieving 'Marginal Gains' to Optimise Outcomes in Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13071669↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith John Roberts · 14 shared papers, 2021–2026 · strength 2.95
  2. Nikolaos A. Chatzizacharias · 5 shared papers, 2023–2026 · strength 1.17
  3. Paul A. H. Moss · 6 shared papers, 2023–2026 · strength 1.12
  4. James Michael Halle-Smith · 5 shared papers, 2023–2024 · strength 1.10
  5. Lewis A Hall · 5 shared papers, 2023–2026 · strength 1.03
  6. Hayden Pearce · 5 shared papers, 2023–2026 · strength 0.93
  7. Wayne D. Croft · 4 shared papers, 2023–2026 · strength 0.71
  8. Sandra Margielewska‐Davies · 4 shared papers, 2023–2026 · strength 0.71
  9. Peter Lawrence Zaki Labib · 3 shared papers, 2026 · strength 0.69
  10. Moath Alarabiyat · 3 shared papers, 2026 · strength 0.69
  11. Robert Peter Sutcliffe · 3 shared papers, 2023–2026 · strength 0.63
  12. Francesca Marcon · 3 shared papers, 2023–2024 · strength 0.47
  13. David Christopher Bartlett · 2 shared papers, 2026 · strength 0.46
  14. S.S. Raza · 2 shared papers, 2026 · strength 0.46
  15. James S. Good · 2 shared papers, 2026 · strength 0.41
  16. Shivan Sivakumar · 2 shared papers, 2026 · strength 0.41
  17. Rupaly Pandé · 2 shared papers, 2021–2023 · strength 0.40
  18. Gary Middleton · 2 shared papers, 2023 · strength 0.30
  19. Nicola de Liguori Carino · 1 shared paper, 2021 · strength 0.22
  20. Francesco Giovinazzo · 1 shared paper, 2024 · strength 0.22
  21. Oonagh M. Griffin · 1 shared paper, 2023 · strength 0.20
  22. Nabeel Merali · 1 shared paper, 2023 · strength 0.19
  23. Adam Enver Frampton · 1 shared paper, 2023 · strength 0.19
  24. Oladimeji Abudu · 1 shared paper, 2024 · strength 0.17
  25. Helen Michelle McGettrick · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.